Welcome to LookChem.com Sign In|Join Free
  • or
1-oxo-2,3-dihydro-1H-inden-5-yl benzoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1149378-95-9

Post Buying Request

1149378-95-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1149378-95-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1149378-95-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,9,3,7 and 8 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1149378-95:
(9*1)+(8*1)+(7*4)+(6*9)+(5*3)+(4*7)+(3*8)+(2*9)+(1*5)=189
189 % 10 = 9
So 1149378-95-9 is a valid CAS Registry Number.

1149378-95-9Relevant academic research and scientific papers

Kinetic resolution of racemic benzofused alcohols catalysed by HMFO variants in presence of natural deep eutectic solvents

Fraaije, Marco,Lon?ar, Nikola,de Gonzalo, Gonzalo

, (2022/03/01)

5-Hydroxymethylfurfural oxidase (HMFO) has demonstrated to be a useful biocatalyst for the selective oxidation of alcohols employing oxygen as mild oxidant with no requirement of expensive organic cofactors. This wild-type HMFO biocatalyst and an engineered thermostable variant have been tested in the kinetic resolution of different benzofused alcohols. The use of natural deep eutectic solvents was also explored in HMFO-catalysed oxidation of alcohols. The oxidation of racemic 1-indanol showed a higher conversion and selectivity in presence of 60% v/v of different NADES, especially for those containing carbohydrates. By choosing properly the biocatalyst and the NADES, good enantioselectivity values can be obtained, demonstrating the advantages of employing these neoteric solvents in biocatalysed processes.

Identification of novel microsomal prostaglandin E2synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening

Lauro, Gianluigi,Manfra, Michele,Pedatella, Silvana,Fischer, Katrin,Cantone, Vincenza,Terracciano, Stefania,Bertamino, Alessia,Ostacolo, Carmine,Gomez-Monterrey, Isabel,De Nisco, Mauro,Riccio, Raffaele,Novellino, Ettore,Werz, Oliver,Campiglia, Pietro,Bifulco, Giuseppe

, p. 278 - 287 (2016/10/03)

Identification of new microsomal prostaglandin E2synthase-1 (mPGES-1) inhibitors is currently sought for the treatment of cancer and inflammation. Here we show the results of a Fragment Virtual Screening campaign using the X-ray crystal structu

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

-

Page/Page column 44, (2015/07/07)

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

-

Page/Page column 44; 45, (2015/07/07)

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC TRICYCLIC COMPOUNDS

-

Page/Page column 24, (2009/06/27)

Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Hydroxy-1-aminoindans and derivatives: Preparation, stability, and reactivity

Herzig, Yaacov,Lerman, Lena,Goldenberg, Willy,Lerner, David,Gottlieb, Hugo E.,Nudelman, Abraham

, p. 4130 - 4140 (2007/10/03)

The chemical stability and reactivity of hydroxy-1-aminoindans and their N-propargyl derivatives are strongly affected by the position of the OH group and its orientation relative to that of the amino moiety. Thus, the 4- and 6-OH regioisomers were found to be stable, while the 5-OH analogues were found to be inherently unstable as the free bases. The latter, having a para orientation between the OH and the amino moieties, could be isolated only as their hydrochloride salts. 7-Hydroxy-1-aminoindans and 7-hydroxy-1- propargylaminoindans represent an intermediate case; while sufficiently stable even as free bases, they exhibit, under certain experimental conditions, unexpected reactivity. The instability of the 5- and 7-hydroxy-aminoindans is attributed to their facile conversion to the corresponding, reactive quinone methide (QM) intermediates. The o-QM obtained from 7-hydroxy-aminoindans was successfully trapped with ethyl vinyl ether via a Diels-Alder reaction to give tricyclic acetals 32a,b.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1149378-95-9